Drug Trial Radar · NCT05813561
The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis
Last checked: Nov 19, 2026Latest source record: Apr 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
332
Actual
Start
Dec 30, 2021
Primary completion
Jul 23, 2022
Study completion Feb 17, 2023
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Apr 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.
Conditions
- Reflux Esophagitis
Interventions
DWP14012Drug
DWP14012 40mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- mucosal healing within 8 weeksTime frame: 8weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Minhu Chen
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.